Drug Use Investigation of Kaletra

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This non-interventional, post-marketing observational study was conducted to obtain data, such as safety and effectiveness, from the use of lopinavir/ritonavir (Kaletra) in clinical practice and investigate the necessity to conduct a follow-up post-marketing clinical study in Japan.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abbott
• Treatments: Lopinavir; Ritonavir

Criteria

Inclusion Criteria:

• All patients prescribed Kaletra for the treatment of HIV are eligible for this survey.

Exclusion Criteria:

• Contraindications according to the Package Insert:

• Patients with a history of hypersensitivity to any ingredient of Kaletra

• Patients who are receiving pimozide, cisapride, ergotamine tartrate, dihydroergotamine mesylate, ergometrine maleate, methylergometrine maleate, midazolam, triazolam, vardenafil hydrochloride hydrate, boriconazol